Kiely John
SEC Form 4 insider trading activity
Kiely John has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Kiely John is listed as Director at Amneal Pharmaceuticals, Inc. Inside the rolling window, Kiely John reported no open-market purchases and 1 open-market sale totaling $882K in AMRX.
Companies traded
Other insiders at AMRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$882K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kiely John made?
Kiely John has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Kiely John trade?
Kiely John has filed SEC Form 4 disclosures for 1 company, including AMRX.
When was Kiely John's most recent SEC Form 4 filing?
Kiely John's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Kiely John's total buy and sell value in the current window?
Inside the rolling retention window, Kiely John bought $0 and sold $882K based on SEC Form 4 filings.
What was Kiely John's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 50,000 AMRX shares on 2026-08-13, worth $882K, per SEC Form 4 filings.